Rocket Lab's $2.36B Backlog Does Not Underwrite An $8B Acquisition

Rocket Lab has a genuinely strong order book and, according to a Seeking Alpha analyst writing under the Out Fox The Street banner, a share price that the order book does not support ^[1]. The reason to care is sequencing rather than sentiment: the planned $8B Iridium acquisition requires heavy equity issuance, while the integration and growth benefits are years away ^[4].

The business side of the argument is not in dispute. The company announced a $2.36B backlog including more than $1B in new contracts, which the analyst reads as evidence of a strong demand climate across the space sector ^[2][3]. That is a large share of the book signed recently: over $1B against $2.36B is more than 42% of total backlog ^[2]. Operators should note what that implies about revenue recognition timing rather than about revenue itself. A backlog is a schedule, not cash, and the schedule depends on vehicles flying.

That is where Neutron comes in. The analyst attributes the valuation gap specifically to Neutron rocket testing delays, arguing the multiple is unsupported while the test programme slips ^[1][5]. Delay does not erase backlog; it moves it right, which is a different problem when the balance sheet is being asked to fund an acquisition in the same window.

The scale mismatch is worth stating plainly. An $8B deal is roughly 3.4 times the announced $2.36B backlog ^[1]. Funded largely with stock, that is dilution taken at today's price against contribution that arrives after integration ^[4]. Shareholders absorb the share count immediately and wait for the synergy story to become revenue.

On valuation, the analyst's numbers are: roughly 50x sales, 40% gross margins, and slowing pro forma growth once Iridium is included ^[6][7][8]. Run the gross margin through the multiple and the equity is being valued at about 125 times gross profit ^[3]. That is a price that assumes both Neutron on schedule and Iridium integrating cleanly. The analyst's conclusion is that the stock price is disconnected from realistic growth and profitability timelines ^[9].

The pro forma growth point deserves more attention than it usually gets. Acquiring a mature, cash-generating business raises revenue and lowers the growth rate at the same time ^[8]. A company valued on growth rate rather than earnings has to explain why a lower blended growth rate deserves the same multiple. Nothing in the backlog answers that.

Worth noting for calibration: the analyst discloses no position, long or short, in any company mentioned ^[10]. This is a valuation argument, not a trade.

What to watch: the equity mix and share count when Iridium deal terms are finalised, since the dilution is the near-term event; Neutron test milestones, because backlog conversion depends on them; and the first pro forma revenue and gross margin figures, which will show whether 40% margins hold once a different business is inside the numbers ^[4][5][7].